Recent News

• 04.10.2025 - Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
• 04.01.2025 - Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
• 03.31.2025 - Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
• 03.13.2025 - Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
• 02.20.2025 - Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
• 02.06.2025 - Video: An Unmet Need in Hyperphosphatemia
• 02.06.2025 - Video: OLC Pipeline
• 02.06.2025 - Video: Our Purpose
• 02.06.2025 - Video: About Unicycive
• 02.05.2025 - Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia

Recent Filings

• 04.01.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - EX-99.1 EX-99.1
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors